Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Teen’s Fight For Lifesaving TB Drug Highlights Access Issues

Executive Summary

An Indian teenager’s court battle for a new tuberculosis drug that doctors say could save her life has cast a harsh spotlight on the slow rollout of breakthrough medicines to treat the disease in the country, one of the world’s biggest TB hotspots.

You may also be interested in...



Call For India Compulsory Licenses For Last Resort TB Drugs

Public health campaigners in India and globally are pushing the government to allow Indian generic firms to make cheap copies of two new-generation, last resort antibiotics for drug-resistant tuberculosis through the use of patent-busting compulsory licenses. 

Otsuka Ties Up With Mylan To Advance MDR-TB Drug In India?

Otsuka, which has been under fire over delayed access to delamanid in India, appears to have allied with Mylan, which has now secured a key clearance for the novel multidrug-resistant TB therapy in the country.

South East Asia Steps Up Fight Against TB

South East Asia is gearing for additional momentum in the fight against TB, a disease that caused nearly 800,000 deaths in the region in 2015. Increased budgetary outlays, a regional “Innovation to Implementation” fund and the need for high impact interventions were among the key issues brought up at a recent ministerial meeting in India.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel